In the Phase III trial, the combination of Padcev and Keytruda improved event-free survival and overall survival in MIBC.

Stoke Therapeutics and Biogen have dosed the first subject in the Phase III EMPEROR trial of zorevunersen for Dravet syndrome treatment.

Novartis' mAb ianalumab helped maintain safe platelet levels for a prolonged period, reducing patient reliance on hospital trips.

The FDA has given the green light for Tiziana Life Sciences’ IND to advance its Phase IIa study of intranasal foralumab for MSA.

The cancer vaccine did not significantly boost progression-free survival (PFS), but IO Biotech plans to seek out its approval anyway.

If approved, Novartis' ianalumab would become the first targeted treatment for patients with Sjögren’s disease.

NHS England is set to offer expedited access to the trial for BioNTech’s new cancer vaccine, BNT113-01, for individuals with advanced head and neck cancers.

Palisade Bio has reported positive outcomes from the Phase Ib open-label cohort of PALI-2108 in those with moderate-to-severe UC.

In July 2025, AbbVie announced top line results from one of two parallel studies of the Phase III UP-AA trial evaluating upadacitinib in alopecia areata (AA).

After the success of the Phase Ib study, Assembly Bio’s herpes therapy will advance to Phase II trials in mid-2026.

The carefully controlled environment of a clinical trial often encounters a significant real-world challenge: concomitant medications.

Lilly's orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral GLP-1RA showed a 13.6% drop in weight.